Gut microbe therapies shrink waistlines in metabolic syndrome, study finds

If you suspect your gut bacteria have something to do with your stubborn midsection, expanding waistline, or blood pressure that will not budge, a new meta-analysis gives that hunch some real, if modest, backing. Researchers pooled 19 randomized controlled trials of probiotics, prebiotics, synbiotics, and fecal microbiota transplants (FMT, the transfer of a donor's gut bacteria into a recipient) in adults with metabolic syndrome, and found the interventions measurably shrank waist size and body weight, even as blood pressure and body mass index stayed flat. The results, published in Obesity Reviews, are a useful reality check on how far gut-focused supplements can actually move the needle on this common cluster of conditions.

Key takeaways:

• Pooling 19 trials (911 participants with metabolic syndrome), probiotics, prebiotics, synbiotics, and FMT modestly reduced waist circumference (by 1.46 cm on average) and body weight (by 1.5 kg on average) compared with placebo or control.
• Body mass index, systolic blood pressure, and diastolic blood pressure showed no statistically significant change across the pooled trials.
• Higher microbial doses, longer treatment courses, and higher starting weight were linked to larger effects on body measurements.
• The headline caveat: heterogeneity between trials was substantial for some outcomes, and none of the individual biomarker changes were large.

Microbiome-Modulating Therapies Trim Waist Circumference and Weight

The core finding is that microbiome-modulating therapies (treatments meant to shift the balance of bacteria living in the gut) produced a statistically significant, if small, reduction in two of five biomarkers tracked in adults with metabolic syndrome: waist circumference and body weight. Pooling data from trial comparisons that measured waist size, researchers led by Pradipta Paul and colleagues at Weill Cornell Medicine-Qatar calculated a mean reduction of 1.46 centimeters (95% confidence interval, -1.99 to -0.92 cm) compared with control groups, a highly consistent result with essentially no disagreement between studies (a heterogeneity statistic, I-squared, of 0.0%). Body weight fell by a mean of 1.50 kilograms (95% CI, -2.00 to -1.00 kg) with similarly low heterogeneity. Both results were statistically significant. Body mass index (BMI, weight adjusted for height) did not move meaningfully, and neither systolic nor diastolic blood pressure showed a consistent pooled effect.

Metabolic Syndrome Affects Millions Who Watch Their Weight and Blood Pressure

Metabolic syndrome is the cluster of central obesity, high blood pressure, insulin resistance, and abnormal cholesterol or triglycerides that raises a person's risk of type 2 diabetes and cardiovascular disease. It is strikingly common: nationally representative US survey data put prevalence at roughly 38.5% of adults in 2021-2023, meaning nearly four in ten adults meet the criteria at any given time. For readers managing prediabetes, high blood pressure, or a growing waistline, and wondering whether their gut bacteria are part of the problem, this study speaks directly to that question, because a shrinking waist is not just cosmetic: central adiposity (fat concentrated around the abdomen) is one of the diagnostic criteria for metabolic syndrome and is closely tied to insulin resistance.

Nineteen Randomized Trials Pooled Across Four Intervention Types

This was not a single new experiment but a systematic review and meta-analysis, a method that combines results from many independent randomized controlled trials (RCTs) to get a more reliable estimate than any one study can provide. The team searched three major databases through April 2023 and screened studies against three internationally recognized metabolic syndrome definitions. They ended up with 19 eligible studies, contributing 21 independent trial comparisons and a total of 911 participants with metabolic syndrome (466 receiving an active intervention, 445 in control or placebo groups). The interventions split across four categories: probiotics (live bacteria, used in 9 of the trials), synbiotics (a combination of probiotics and fibers that feed them, 6 trials), prebiotics (fermentable fibers alone, 3 trials), and FMT (3 trials). Median treatment length was 12 weeks, ranging from as short as 2 weeks to as long as 24 weeks, and participants in both intervention and control groups started with a median body mass index around 32, placing them in the obese range. A formal bias assessment using the Cochrane Risk of Bias tool rated 18 of the 21 trial comparisons as low overall risk of bias and none as high risk, which supports treating the pooled estimates as reasonably trustworthy.

What This Means if You Are Considering a Probiotic for Weight or Blood Pressure

For a reader weighing whether to try a probiotic, synbiotic, or other gut-targeted supplement for weight or blood pressure control, this study supports cautious optimism about waist size and weight, and skepticism about blood pressure. A roughly 1.5-centimeter reduction in waist circumference or 1.5-kilogram reduction in body weight is real but small, not a substitute for established interventions like diet changes, physical activity, or medications your doctor may recommend for metabolic syndrome. The researchers themselves describe these therapies as potentially complementing, not replacing, lifestyle strategies. Meta-regression analysis found that trials using higher microbial doses, running longer than 12 weeks, and enrolling people with higher starting body weight tended to show larger effects on body measurements, which suggests dose and duration matter if these interventions do anything at all. Nothing in this study should be read as evidence that a specific probiotic strain or supplement is a proven treatment for metabolic syndrome; the trials tested a wide range of different formulations, doses, and delivery methods (from fermented milk to capsules to donor stool), and no single product was validated.

Trial Heterogeneity and Unmoved Blood Pressure Remain Open Questions

The clearest limitation is that the trials backing this analysis were not uniform. The pooled BMI result, unlike waist circumference and weight, showed high heterogeneity (I-squared of 87.5%), meaning individual trials disagreed substantially with each other, and the overall BMI effect was not statistically significant (mean difference of -0.20 kg/m2, 95% CI -0.47 to 0.07, p=0.141). Blood pressure fared even less consistently: systolic blood pressure showed a non-significant pooled mean difference of +0.17 mmHg (95% CI -2.81 to 3.15, p=0.912) and diastolic blood pressure a non-significant +0.27 mmHg (95% CI -1.84 to 2.39, p=0.799), with moderate to substantial heterogeneity in both. In plain terms, across these 19 studies, gut-targeted therapies simply did not move blood pressure in a consistent direction, despite some individual trials reporting reductions. The authors also note that formal statistical tests comparing intervention subgroups, such as synbiotics versus probiotics alone, did not reach significance, so claims that one type of therapy outperforms another remain unproven.

Larger, Standardized Trials With Microbiome Profiling Are the Next Step

The study's authors call for larger, more standardized trials that pair anthropometric and blood pressure measurements with actual microbiome profiling (sequencing which bacterial species shift with treatment), something most of the 19 included trials did not do. That kind of design would let researchers connect a specific microbial change to a specific health outcome rather than just observing that a category of supplement was associated with a small effect. Separately, other recent RCTs have tested more targeted approaches, such as a controlled trial of pasteurized Akkermansia muciniphila for weight-loss maintenance, and a broader umbrella review of gut microbiome modulation in metabolic syndrome reached similar conclusions about anthropometric benefits. Expect more single-strain and dose-ranging studies before any specific product earns a strong recommendation.

Common Questions

Do probiotics actually help with metabolic syndrome? This meta-analysis found a small but statistically significant reduction in waist circumference and body weight from probiotics, prebiotics, synbiotics, and FMT combined, but no significant effect on BMI or blood pressure, so the honest answer is "modestly, for some measures, not others."

Which type of gut therapy worked best, probiotics, prebiotics, synbiotics, or FMT? Synbiotics showed numerically larger reductions in some analyses, but the study's own statistical tests found the differences between intervention types were not significant, so no single category can be called superior based on this evidence.

Should someone with metabolic syndrome take a probiotic instead of standard treatment? No. The study authors describe these interventions as a possible complement to established lifestyle and medical strategies, not a replacement, and no specific product was validated as an established treatment.

How long did people take these supplements in the studies? Trial durations in the pooled studies ranged from 2 to 24 weeks, with a median of 12 weeks, and longer trials tended to show larger effects on waist size and weight.

References

1. Pradipta Paul, Iman Dajani, Ridhima Kaul, Ali Chaari (2026). The Effect of Microbiome‐Modulating Therapeutics on Anthropometric and Hemodynamic Biomarkers in Metabolic Syndrome: A Systematic Review, Meta‐Analysis, and Meta‐Regression of Clinical Trials. Obesity Reviews. https://doi.org/10.1111/obr.70215
2. Shady Abohashem, Ibrahim Hassan, Jason H. Wasfy, Pam R. Taub (2026). Trends and Prevalence of the Metabolic Syndrome Among US Adults. JAMA. https://doi.org/10.1001/jama.2025.21712
3. Sarah Mount, Emanuel E. Canfora, Johan W. Jocken, et al. (2026). Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04394-7
4. Maryam Sadat Aleali, Abinash Mahapatro, Gautam Maddineni, et al. (2025). The impact of gut microbiome modulation on anthropometric indices in metabolic syndrome: an umbrella review. Annals of Medicine & Surgery. https://doi.org/10.1097/ms9.0000000000003140